The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 07, 2025

Filed:

Mar. 27, 2023
Applicant:

Isosterix, Inc., San Carlos, CA (US);

Inventors:

Roopa Rai, San Carlos, CA (US);

Mark Bures, Zionsville, IN (US);

Assignee:

Isosterix, Inc., San Carlos, CA (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 487/04 (2006.01); A61P 35/00 (2006.01); C07D 213/56 (2006.01); C07D 307/85 (2006.01); C07D 401/04 (2006.01); C07D 405/12 (2006.01); C07D 413/04 (2006.01); C07D 413/06 (2006.01); C07D 413/12 (2006.01); C07D 213/46 (2006.01); C07D 231/12 (2006.01); C07D 231/38 (2006.01); C07D 413/08 (2006.01); C07D 413/10 (2006.01); C07D 413/14 (2006.01); C07D 471/04 (2006.01); C07D 519/00 (2006.01);
U.S. Cl.
CPC ...
C07D 487/04 (2013.01); A61P 35/00 (2018.01); C07D 213/56 (2013.01); C07D 307/85 (2013.01); C07D 401/04 (2013.01); C07D 405/12 (2013.01); C07D 413/04 (2013.01); C07D 413/06 (2013.01); C07D 413/12 (2013.01);
Abstract

Provided herein are compounds of Formula (I). Methods for the preparation of the compounds of Formula (I) and intermediates useful in the preparation of the compounds of Formula (I) are described herein. The compounds of Formula (I) may be useful as inhibitors of the MYST family of lysine acetyltransferases (KATs) for the treatment of and/or prophylaxis of hyperproliferative diseases, disorders or conditions such as cancer. In particular, the compounds of Formula (I) are useful for the inhibition of KAT6A and KAT6B which are enzymes frequently mutated, overexpressed, amplified and/or translocated in cancer altering their normal expression, activity and function. The use of the compounds of Formula (I) in the manufacture of pharmaceutical compositions or for treating cancers is further described, including for treating cancer in combination with other anti-cancer agents.


Find Patent Forward Citations

Loading…